Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is the most common liver disorder worldwide, with an estimated global prevalence of more than 31%. Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), is a progressive form of MASLD characterized by hepatic steatosis, inflammation, and fibrosis. This review aims to provide a comprehensive analysis of the extrahepatic manifestations of MASH, focusing on chronic diseases related to the cardiovascular, muscular, and renal systems. A systematic review of published studies and literature was conducted to summarize the findings related to the systemic impacts of MASLD and MASH. The review focused on the association of MASLD and MASH with metabolic comorbidities, cardiovascular mortality, sarcopenia, and chronic kidney disease. Mechanistic insights into the concept of lipotoxic inflammatory “spill over” from the MASH-affected liver were also explored. MASLD and MASH are highly associated (50%–80%) with other metabolic comorbidities such as impaired insulin response, type 2 diabetes, dyslipidemia, hypertriglyceridemia, and hypertension. Furthermore, more than 90% of obese patients with type 2 diabetes have MASH. Data suggest that in middle-aged individuals (especially those aged 45–54), MASLD is an independent risk factor for cardiovascular mortality, sarcopenia, and chronic kidney disease. The concept of lipotoxic inflammatory “spill over” from the MASH-affected liver plays a crucial role in mediating the systemic pathological effects observed. Understanding the multifaceted impact of MASH on the heart, muscle, and kidney is crucial for early detection and risk stratification. This knowledge is also timely for implementing comprehensive disease management strategies addressing multi-organ involvement in MASH pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and metabolic disorders
Hotamisligil, G. S. (2006) · Nature · doi:10.1038/nature05485 · Cited by 9,199 · cited 1×
“Moreover, IS was also found to be increased in MASLD patients (Hotamisligil, 2006; Ribeiro et al., 2023).”
BackgroundA Novel Paradigm for Heart Failure With Preserved Ejection Fraction
Paulus, W. J., & Tschöpe, C. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.092 · Cited by 3,564
Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023) · Hepatology · doi:10.1097/hep.0000000000000004 · Cited by 3,383
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Buzzetti, E., Pinzani, M., & Tsochatzis, E. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.12.012 · Cited by 3,119
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Non-alcoholic fatty liver disease
Powell, E. E., Wong, V. W.-S., & Rinella, M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32511-3 · Cited by 2,789
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002 · cited 4×
“IR fosters in fl ammation and oxidative stress, contributing to liver cell injury and disease progression (Loomba et al., 2021; Muzurovic et al., 2022; Njoku et al., 2022).”
BackgroundInfluentialSkeletal muscle: A brief review of structure and function
Frontera, W. R., & Ochala, J. (2015) · Calcified Tissue International · doi:10.1007/s00223-014-9915-y · Cited by 1,758
Retinol-Binding Protein 4 and Insulin Resistance in Lean, Obese, and Diabetic Subjects
Graham, T. E., Yang, Q., Blüher, M., Hammarstedt, A., Ciaraldi, T. P., Henry, R. R., Wason, C. J., Oberbach, A., Jansson, P.-A., Smith, U., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054862 · Cited by 1,319
Ganz, T., & Nemeth, E. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.01.014 · Cited by 1,282
Tang, W. H. W., Wang, Z., Kennedy, D. J., Wu, Y., Buffa, J. A., Agatisa-Boyle, B., Li, X. S., Levison, B. S., & Hazen, S. L. (2015) · Circulation Research · doi:10.1161/circresaha.116.305360 · Cited by 1,223
Omega-3 Fatty Acids and Inflammatory Processes
Calder, P. C. (2010) · Nutrients · doi:10.3390/nu2030355 · Cited by 1,116
Exerkines in health, resilience and disease
Chow, L. S., Gerszten, R. E., Taylor, J. M., Pedersen, B. K., van Praag, H., Trappe, S., Febbraio, M. A., Galis, Z. S., Gao, Y., Haus, J. M., et al. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00641-2 · Cited by 927
Nogal, A., Valdes, A. M., & Menni, C. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1897212 · Cited by 917
Ryan, M. C., Itsiopoulos, C., Thodis, T., Ward, G., Trost, N., Hofferberth, S., O’Dea, K., Desmond, P. V., Johnson, N. A., & Wilson, A. M. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.02.012 · Cited by 778
Changing epidemiology, global trends and implications for outcomes of NAFLD
Wong, V. W.-S., Ekstedt, M., Wong, G. L.-H., & Hagström, H. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.036 · Cited by 765
Lai, J. C., Tandon, P., Bernal, W., Tapper, E. B., Ekong, U., Dasarathy, S., & Carey, E. J. (2021) · Hepatology · doi:10.1002/hep.32049 · Cited by 742
Sarcopenia and Cardiovascular Diseases
Damluji, A. A., Alfaraidhy, M., AlHajri, N., Rohant, N. N., Kumar, M., Al Malouf, C., Bahrainy, S., Ji Kwak, M., Batchelor, W. B., Forman, D. E., et al. (2023) · Circulation · doi:10.1161/circulationaha.123.064071 · Cited by 645 · cited 1×
“This condition, beyond being a mere consequence of aging, is increasingly recognized as a progressive disease linked with higher risks of obesity, T2D, osteoporosis, CVDs, and cancer (Purnamasari et al., 2022; Yu et al., 2022; Damluji et al., 2023).”
BackgroundFGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis
Kir, S., Beddow, S. A., Samuel, V. T., Miller, P., Previs, S. F., Suino-Powell, K., Xu, H. E., Shulman, G. I., Kliewer, S. A., & Mangelsdorf, D. J. (2011) · Science · doi:10.1126/science.1198363 · Cited by 637
A liver-derived secretory protein, selenoprotein P, causes insulin resistance
Misu, H., Takamura, T., Takayama, H., Hayashi, H., Matsuzawa-Nagata, N., Kurita, S., Ishikura, K., Ando, H., Takeshita, Y., Ota, T., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.09.015 · Cited by 583
Hallsworth, K., Fattakhova, G., Hollingsworth, K. G., Thoma, C., Moore, S., Taylor, R., Day, C. P., & Trenell, M. I. (2011) · Gut · doi:10.1136/gut.2011.242073 · Cited by 529
Montano-Loza, A. J., Angulo, P., Meza-Junco, J., Prado, C. M. M., Sawyer, M. B., Beaumont, C., Esfandiari, N., Ma, M., & Baracos, V. E. (2016) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12039 · Cited by 512
Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake
Merz, K. E., & Thurmond, D. C. (2020) · Comprehensive Physiology · doi:10.1002/cphy.c190029 · Cited by 494
NAFLD as a driver of chronic kidney disease
Byrne, C. D., & Targher, G. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.01.013 · Cited by 449
Fatty liver hepatitis and cirrhosis in obese patients
Adler, M., & Schaffner, F. (1979) · The American Journal of Medicine · doi:10.1016/0002-9343(79)90740-x · Cited by 399
Myostatin and the skeletal muscle atrophy and hypertrophy signaling pathways
Rodriguez, J., Vernus, B., Chelh, I., Cassar-Malek, I., Gabillard, J. C., Hadj Sassi, A., Seiliez, I., Picard, B., & Bonnieu, A. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1689-x · Cited by 397 · cited 1×
“Myostatin inhibits muscle differentiation and protein synthesis by activating the SMAD2/3 signaling pathway, leading to muscle atrophy (Rodriguez et al., 2014).”
BackgroundSkeletal Muscle as an Endocrine Organ: The Role of Myokines in Exercise Adaptations
Hoffmann, C., & Weigert, C. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a029793 · Cited by 393
Hong, H. C., Hwang, S. Y., Choi, H. Y., Yoo, H. J., Seo, J. A., Kim, S. G., Kim, N. H., Baik, S. H., Choi, D. S., & Choi, K. M. (2014) · Hepatology · doi:10.1002/hep.26716 · Cited by 385 · cited 1×
“These mediators can exacerbate pathological processes in the heart, skeletal muscle, and kidneys, contributing to the multisystem impact of the disease (Hong et al., 2014; Buzzetti et al., 2016; Machado and Diehl, 2016; Bhanji et al., 2017a; Mitten and Baffy, 2022).”
BackgroundNonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment
Llovet, J. M., Willoughby, C. E., Singal, A. G., Greten, T. F., Heikenwälder, M., El-Serag, H. B., Finn, R. S., & Friedman, S. L. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00754-7 · Cited by 354
Mediterranean diet and nonalcoholic fatty liver disease
Anania, C., Perla, F. M., Olivero, F., Pacifico, L., & Chiesa, C. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i19.2083 · Cited by 353
Younossi, Z. M., Paik, J. M., Stepanova, M., Ong, J., Alqahtani, S., & Henry, L. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.01.014 · Cited by 321
Angiopoietin-Like Proteins: A Comprehensive Look
Santulli, G. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00004 · Cited by 320
Le, M. H., Le, D. M., Baez, T. C., Wu, Y., Ito, T., Lee, E. Y., Lee, K., Stave, C. D., Henry, L., Barnett, S. D., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.040 · Cited by 303 · cited 3×
“%) with impaired insulin response, type 2 diabetes, dyslipidaemia, hypertriglyceridemia, hypertension, and more than 90% of obese patients with type 2 diabetes have MASH (Le et al., 2023).”
BackgroundInfluentialZhang, X., Li, Y., Yang, P., Liu, X., Lu, L., Chen, Y., Zhong, X., Li, Z., Liu, H., Ou, C., et al. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.313414 · Cited by 291
Hepatokines and metabolism: Deciphering communication from the liver
Jensen-Cody, S. O., & Potthoff, M. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101138 · Cited by 252
Leptin in nonalcoholic fatty liver disease: A narrative review
Polyzos, S. A., Kountouras, J., & Mantzoros, C. S. (2015) · Metabolism · doi:10.1016/j.metabol.2014.10.012 · Cited by 235
The Role of Oxidative Stress in Skeletal Muscle Myogenesis and Muscle Disease
Lian, D., Chen, M.-M., Wu, H., Deng, S., & Hu, X. (2022) · Antioxidants · doi:10.3390/antiox11040755 · Cited by 232
Impact of different ectopic fat depots on cardiovascular and metabolic diseases
Ferrara, D., Montecucco, F., Dallegri, F., & Carbone, F. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28821 · Cited by 195
Adipokines, Myokines, and Hepatokines: Crosstalk and Metabolic Repercussions
de Oliveira dos Santos, A. R., de Oliveira Zanuso, B., Miola, V. F. B., Barbalho, S. M., Santos Bueno, P. C., Flato, U. A. P., Detregiachi, C. R. P., Buchaim, D. V., Buchaim, R. L., Tofano, R. J., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052639 · Cited by 189
Fibroblast growth factor 21: a regulator of metabolic disease and health span
Xie, T., & Leung, P. S. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00101.2017 · Cited by 121
Nachit, M., Kwanten, W. J., Thissen, J.-P., Op De Beeck, B., Van Gaal, L., Vonghia, L., Verrijken, A., Driessen, A., Horsmans, Y., Francque, S., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.02.037 · Cited by 114
van der Meer, R. W., Hammer, S., Lamb, H. J., Frölich, M., Diamant, M., Rijzewijk, L. J., de Roos, A., Romijn, J. A., & Smit, J. W. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2524 · Cited by 113
Fontes-Cal, T. C. M., Mattos, R. T., Medeiros, N. I., Pinto, B. F., Belchior-Bezerra, M., Roque-Souza, B., Dutra, W. O., Ferrari, T. C. A., Vidigal, P. V. T., Faria, L. C., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.708959 · Cited by 97
Ristic-Medic, D., Kovacic, M., Takic, M., Arsic, A., Petrovic, S., Paunovic, M., Jovicic, M., & Vucic, V. (2020) · Nutrients · doi:10.3390/nu13010015 · Cited by 81
Interaction between sarcopenia and nonalcoholic fatty liver disease
Joo, S. K., & Kim, W. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0358 · Cited by 78
Non-alcoholic fatty liver disease: pathogenesis and models
Zhong, H. (2024) · American Journal of Translational Research · doi:10.62347/kmsa5983 · Cited by 37
Thyroid hormones and thyromimetics: a new approach to nonalcoholic steatohepatitis?
Sinha, R. A., Bruinstroop, E., Singh, B. K., & Yen, P. M. (2020) · Hepatology · doi:10.1002/hep.31204 · Cited by 17 · cited 1×
“The exploration of thyromimetics, which mimic thyroid hormone actions to regulate metabolism, demonstrates potential in ameliorating MASH-related liver damage, in fl ammation, and fi brosis, as evidenced by clinical trials with agents like resmetirom (Sinha et al., 2020).”
BackgroundSelf-citation
Research works printed but not linked: 175
- Alonso-Pena, 2023, Innovative therapeutic approaches in non-alcoholic fatty liver disease: when knowing your patient is key, Int. J. Mol. Sci., 24, 10718, 10.3390/ijms241310718 · DOI
- Anstee, 2020, Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort(☆), J. Hepatol., 73, 505, 10.1016/j.jhep.2020.04.003 · DOI · Paper page
- Arslan, 2020, Relationship between non-alcoholic fatty liver disease and coronary heart disease, World J. Clin. Cases., 8, 4688, 10.12998/wjcc.v8.i20.4688 · DOI
- Ballestri, 2014, Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease, World J. Gastroenterol., 20, 1724, 10.3748/wjg.v20.i7.1724 · DOI · Paper page
- Barreto, 2009, Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients, Clin. J. Am. Soc. Nephrol., 4, 1551, 10.2215/CJN.03980609 · DOI · Paper page
- Berezin, 2023, Cardiac hepatopathy: new perspectives on old problems through a prism of endogenous metabolic regulations by hepatokines, Antioxidants (Basel), 12, 516, 10.3390/antiox12020516 · DOI
- Bhanji, The long winding road to transplant: how sarcopenia and debility impact morbidity and mortality on the waitlist, Clin. Gastroenterol. Hepatol., 15, 1492, 10.1016/j.cgh.2017.04.004 · DOI
- Bhanji, Sarcopenia in hiding: the risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis, Hepatology, 66, 2055, 10.1002/hep.29420 · DOI · Paper page
- Bian, 2013, CCN1 expression in hepatocytes contributes to macrophage infiltration in nonalcoholic fatty liver disease in mice, J. Lipid. Res., 54, 44, 10.1194/jlr.M026013 · DOI · Paper page
- Bilson, 2023, Steatotic liver disease, MASLD and risk of chronic kidney disease, Diabetes. Metab., 50, 101506, 10.1016/j.diabet.2023.101506 · DOI · Paper page
- Boesch, 2023, Adipose tissue macrophage dysfunction is associated with a breach of vascular integrity in NASH, J. Hepatol., 80, 397, 10.1016/j.jhep.2023.10.039 · DOI
- Brody, 2020, The gut microbiome, Nature, 577, S5, 10.1038/d41586-020-00194-2 · doi:10.1038/d41586-020-00194-2
- Byrne, 2013, Ectopic fat, insulin resistance and non-alcoholic fatty liver disease, Proc. Nutr. Soc., 72, 412, 10.1017/S0029665113001249 · DOI
- Camici, 2007, Coronary microvascular dysfunction, N. Engl. J. Med., 356, 830, 10.1056/NEJMra061889 · DOI · Paper page
- Cao, 2021, The association between NAFLD and risk of chronic kidney disease: a cross-sectional study, Ther. Adv. Chronic. Dis., 12, 20406223211048649, 10.1177/20406223211048649 · DOI
- Castillo-Rodriguez, 2018, Impact of altered intestinal microbiota on chronic kidney disease progression, Toxins (Basel), 10, 300, 10.3390/toxins10070300 · DOI · Paper page
- Chakravarthy, 2020, Harnessing muscle-liver crosstalk to treat nonalcoholic steatohepatitis, Front. Endocrinol. (Lausanne), 11, 592373, 10.3389/fendo.2020.592373 · DOI · Paper page
- Chang, 2019, Evaluation of left atrial function in type 2 diabetes mellitus patients with nonalcoholic fatty liver disease by two-dimensional speckle tracking echocardiography, Echocardiography, 36, 1290, 10.1111/echo.14400 · DOI
- Chaudhry, 2019, Immune cell trafficking to the liver, Transplantation, 103, 1323, 10.1097/TP.0000000000002690 · DOI
- Choe, 2024, Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: a community-dwelling cohort study with 20-year follow-up, Metabolism, 153, 155800, 10.1016/j.metabol.2024.155800 · DOI
- Cusi, 2024, From NAFLD to MASLD: promise and pitfalls of a new definition †, Hepatology, 79, E13, 10.1097/HEP.0000000000000706 · DOI
- Deacon, 2011, Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review, Diabetes. Obes. Metab., 13, 7, 10.1111/j.1463-1326.2010.01306.x · DOI · Paper page
- Del, 2021, Coronary microvascular dysfunction across the spectrum of cardiovascular diseases: JACC state-of-the-art review, J. Am. Coll. Cardiol., 78, 1352, 10.1016/j.jacc.2021.07.042 · DOI · Paper page
- Delgado-Marin, 2024, Indoxyl sulfate-induced valve endothelial cell endothelial-to-mesenchymal transition and calcification in an integrin-linked kinase-dependent manner, Cells, 13, 481, 10.3390/cells13060481 · doi:10.3390/cells13060481
- Dhindsa, 2018, Hypogonadotropic hypogonadism in men with diabesity, Diabetes .Care., 41, 1516, 10.2337/dc17-2510 · DOI · Paper page
- Dimitroglou, 2023, Novel anti-inflammatory therapies in coronary artery disease and acute coronary syndromes, Life (Basel), 13, 1669, 10.3390/life13081669 · DOI
- Duan, 2022, Association of inflammatory cytokines with non-alcoholic fatty liver disease, Front. Immunol., 13, 880298, 10.3389/fimmu.2022.880298 · DOI · Paper page
- Ebert, 2014, Circulating angiopoietin-like protein 8 is independently associated with fasting plasma glucose and type 2 diabetes mellitus, J. Clin. Endocrinol. Metab., 99, E2510, 10.1210/jc.2013-4349 · DOI
- Estes, 2020, Modelling NAFLD disease burden in four Asian regions-2019-2030, Aliment. Pharmacol. Ther., 51, 801, 10.1111/apt.15673 · DOI · Paper page
- Estes, 2018, Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease, Hepatol., 67, 123, 10.1002/hep.29466 · DOI · Paper page
- Fan Xz, 2024, Systemic metabolic Abnormalities: key drivers of complications and mortality in MASLD, J. Hepatol., 80, e246, 10.1016/j.jhep.2024.02.001 · DOI
- Garbuzenko, 2022, Pathophysiological mechanisms of cardiovascular disorders in non-alcoholic fatty liver disease, Gastroenterol. Hepatol. Bed. Bench., 15, 194, 10.22037/ghfbb.v15i3.2549 · DOI
- Gilani, 2024, Adipose signals regulating distal organ health and disease, Diabetes, 73, 169, 10.2337/dbi23-0005 · DOI
- Gonzalez, 2020, Role of oxidative stress in hepatic and extrahepatic dysfunctions during nonalcoholic fatty liver disease (NAFLD), Oxid. Med. Cell. Longev., 2020, 1617805, 10.1155/2020/1617805 · DOI
- Gumucio, 2019, Reduced mitochondrial lipid oxidation leads to fat accumulation in myosteatosis, FASEB J., 33, 7863, 10.1096/fj.201802457RR · DOI
- Habibullah, 2024, Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies, Front. Med. (Lausanne), 11, 1291501, 10.3389/fmed.2024.1291501 · DOI
- Hafiane, 2024, Adiponectin-mediated regulation of the adiponectin cascade in cardiovascular disease: updates, Biochem. Biophys. Res. Commun., 694, 149406, 10.1016/j.bbrc.2023.149406 · DOI
- Hallsworth, 2013, Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease, J. Hepatol., 58, 757, 10.1016/j.jhep.2012.11.015 · DOI
- Han, 2015, p-Cresyl sulfate aggravates cardiac dysfunction associated with chronic kidney disease by enhancing apoptosis of cardiomyocytes, J. Am. Heart. Assoc., 4, e001852, 10.1161/JAHA.115.001852 · DOI
- Holecek, 2021, The role of skeletal muscle in the pathogenesis of altered concentrations of branched-chain amino acids (valine, leucine, and isoleucine) in liver cirrhosis, diabetes, and other diseases, Physiol. Res., 70, 293, 10.33549/physiolres.934648 · DOI
- Houghton, 2019, The degree of hepatic steatosis associates with impaired cardiac and autonomic function, J. Hepatol., 70, 1203, 10.1016/j.jhep.2019.01.035 · DOI · Paper page
- Huang, 2022, Shared mechanisms between cardiovascular disease and NAFLD, Semin. Liver. Dis., 42, 455, 10.1055/a-1930-6658 · DOI
- Huang, 2023, Performance of nonalcoholic fatty liver fibrosis score in estimating atherosclerotic cardiovascular disease risk, Nutr. Metab. Cardiovasc. Dis., 33, 2479, 10.1016/j.numecd.2023.08.005 · DOI
- Ismaiel, 2019, Cardiovascular risk in fatty liver disease: the liver-heart axis-literature review, Front. Med. (Lausanne), 6, 202, 10.3389/fmed.2019.00202 · DOI · Paper page
- Iwakiri, 2021, Portal hypertension in cirrhosis: pathophysiological mechanisms and therapy, JHEP Rep., 3, 100316, 10.1016/j.jhepr.2021.100316 · DOI · Paper page
- Jacobs, 2014, Heart 'omics' in AGEing (HOMAGE): design, research objectives and characteristics of the common database, J. Biomed. Res., 28, 349, 10.7555/JBR.28.20140045 · DOI
- Jensen, 2018, Fructose and sugar: a major mediator of non-alcoholic fatty liver disease, J. Hepatol., 68, 1063, 10.1016/j.jhep.2018.01.019 · DOI · Paper page
- Jia, 2024, Exercise alleviates aging of adipose tissue through adipokine regulation, Metabolites, 14, 135, 10.3390/metabo14030135 · DOI
- Jiang, 2024, Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics, Lipids. Health. Dis., 23, 95, 10.1186/s12944-024-02092-2 · DOI
- Jimenez, 2018, FGF21 gene therapy as treatment for obesity and insulin resistance, EMBO Mol. Med., 10, e8791, 10.15252/emmm.201708791 · DOI · Paper page
- Kang, 2023, Sarcopenic obesity, the possible culprit for nonalcoholic fatty liver disease or fibrosis, Gut. Liver., 17, 8, 10.5009/gnl220543 · DOI
- Kasper, 2021, NAFLD and cardiovascular diseases: a clinical review, Clin. Res. Cardiol., 110, 921, 10.1007/s00392-020-01709-7 · DOI · Paper page
- Katsiki, 2021, Serum uric acid and diabetes: from pathophysiology to cardiovascular disease, Curr. Pharm. Des., 27, 1941, 10.2174/1381612827666210104124320 · DOI
- Kawaguchi, 2023, Clinics in liver disease: update on nonalcoholic steatohepatitis: sarcopenia and nonalcoholic fatty liver disease, Clin. Liver. Dis., 27, 275, 10.1016/j.cld.2023.01.005 · DOI
- Khan, 2022, Non-alcoholic fatty liver disease and liver secretome, Arch. Pharm. Res., 45, 938, 10.1007/s12272-022-01419-w · DOI
- Koplay, 2011, Association between serum vitamin B12 levels and the degree of steatosis in patients with nonalcoholic fatty liver disease, J. Investig. Med., 59, 1137, 10.2310/JIM.0b013e31822a29f5 · DOI
- Krishnan, 2014, IL-1beta and IL-18: inflammatory markers or mediators of hypertension?, Br. J. Pharmacol., 171, 5589, 10.1111/bph.12876 · DOI · Paper page
- Kumar, 2008, Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism, Cell. Metab., 8, 468, 10.1016/j.cmet.2008.10.011 · DOI · Paper page
- Lebeaupin, 2018, Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease, J. Hepatol., 69, 927, 10.1016/j.jhep.2018.06.008 · DOI · Paper page
- Lee, 1999, Myostatin and the control of skeletal muscle mass, Curr. Opin. Genet. Dev., 9, 604, 10.1016/s0959-437x(99)00004-0 · DOI · Paper page
- Lee, 2015, Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: nationwide surveys (KNHANES 2008-2011), J. Hepatol., 63, 486, 10.1016/j.jhep.2015.02.051 · DOI · Paper page
- Lee, 2018, Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients, J. Hepatol., 68, 764, 10.1016/j.jhep.2017.11.023 · DOI
- Levy, 2021, Cardiovascular manifestations of intermediate and major hyperhomocysteinemia due to vitamin B12 and folate deficiency and/or inherited disorders of one-carbon metabolism: a 3.5-year retrospective cross-sectional study of consecutive patients, Am. J. Clin. Nutr., 113, 1157, 10.1093/ajcn/nqaa432 · DOI
- Li, 2011, Leptin and beyond: an odyssey to the central control of body weight, Yale J. Biol. Med., 84, 1
- Li, 2023, Chronic kidney disease in a murine model of non-alcoholic steatohepatitis (NASH), Kidney. Int., 105, 540, 10.1016/j.kint.2023.12.009 · DOI
- Lim, 2019, Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome, Obes. Rev., 20, 599, 10.1111/obr.12820 · DOI
- Lim, 2023, Natural history of NASH cirrhosis in liver transplant waitlist registrants, J. Hepatol., 79, 1015, 10.1016/j.jhep.2023.05.034 · DOI
- Linton, 2000, Endotext
- Liu, 2015, The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy, Metabolism, 64, 380, 10.1016/j.metabol.2014.11.009 · DOI
- Lundberg, 2021, Idiopathic inflammatory myopathies, Nat. Rev. Dis. Prim., 7, 86, 10.1038/s41572-021-00321-x · DOI · Paper page
- Machado, 2021, Aerobic exercise in the management of metabolic dysfunction associated fatty liver disease, Diabetes Metab. Syndr. Obes., 14, 3627, 10.2147/DMSO.S304357 · DOI · Paper page
- Machado, 2016, Pathogenesis of nonalcoholic steatohepatitis, Gastroenterol., 150, 1769, 10.1053/j.gastro.2016.02.066 · DOI · Paper page
- Mahamid, 2018, Folate and B12 levels correlate with histological severity in NASH patients, Nutrients, 10, 440, 10.3390/nu10040440 · DOI
- Mahmoudi, 2024, Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches, Eur. J. Med. Res., 29, 190, 10.1186/s40001-024-01708-8 · DOI
- Mantovani, 2022, Risk of heart failure in patients with nonalcoholic fatty liver disease: JACC review topic of the week, J. Am. Coll. Cardiol., 79, 180, 10.1016/j.jacc.2021.11.007 · DOI · Paper page
- Mantovani, 2019, Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: an updated meta-analysis, Liver. Int., 39, 758, 10.1111/liv.14044 · DOI · Paper page
- Marcuccilli, 2016, NAFLD and chronic kidney disease, Int. J. Mol. Sci., 17, 562, 10.3390/ijms17040562 · DOI · Paper page
- Medrano-Bosch, 2023, Monocyte-endothelial cell interactions in vascular and tissue remodeling, Front. Immunol., 14, 1196033, 10.3389/fimmu.2023.1196033 · DOI · Paper page
- Meijers, 2010, p-Cresol and cardiovascular risk in mild-to-moderate kidney disease, Clin. J. Am. Soc. Nephrol., 5, 1182, 10.2215/CJN.07971109 · DOI · Paper page
- Mendez-Sanchez, 2020, Dyslipidemia as a risk factor for liver fibrosis progression in a multicentric population with non-alcoholic steatohepatitis, F1000Res, 9, 56, 10.12688/f1000research.21918.1 · DOI
- Meng, 2016, Relationship between grip strength and newly diagnosed nonalcoholic fatty liver disease in a large-scale adult population, Sci. Rep., 6, 33255, 10.1038/srep33255 · DOI · Paper page
- Meyer, 2020, Molecular mechanism contributing to malnutrition and sarcopenia in patients with liver cirrhosis, Int. J. Mol. Sci., 21, 5357, 10.3390/ijms21155357 · DOI
- Mitten, 2022, Mechanotransduction in the pathogenesis of non-alcoholic fatty liver disease, J. Hepatol., 77, 1642, 10.1016/j.jhep.2022.08.028 · DOI · Paper page
- Mohammed, 2014, Right ventricular function in heart failure with preserved ejection fraction: a community-based study, Circulation, 130, 2310, 10.1161/CIRCULATIONAHA.113.008461 · DOI · Paper page
- Mounier, 2013, AMPKα1 regulates macrophage skewing at the time of resolution of inflammation during skeletal muscle regeneration, Cell. Metab., 18, 251, 10.1016/j.cmet.2013.06.017 · DOI · Paper page
- Murthy, 2011, Improved cardiac risk assessment with noninvasive measures of coronary flow reserve, Circulation, 124, 2215, 10.1161/CIRCULATIONAHA.111.050427 · DOI · Paper page
- Musa-Veloso, 2018, Systematic review and meta-analysis of controlled intervention studies on the effectiveness of long-chain omega-3 fatty acids in patients with nonalcoholic fatty liver disease, Nutr. Rev., 76, 581, 10.1093/nutrit/nuy022 · DOI · Paper page
- Musso, 2014, Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis, PLoS. Med., 11, e1001680, 10.1371/journal.pmed.1001680 · DOI · Paper page
- Muzurovic, 2022, Nonalcoholic fatty liver disease and cardiovascular disease: a review of shared cardiometabolic risk factors, Hypertension, 79, 1319, 10.1161/HYPERTENSIONAHA.122.17982 · DOI
- Nahandi, 2014, Effect of non-alcoholic fatty liver disease on carotid artery intima-media thickness as a risk factor for atherosclerosis, Gastroenterol. Hepatol. Bed. Bench., 7, 55
- Njoku, 2022, Mechanisms of nonalcoholic steatohepatitis-associated cardiomyopathy: key roles for liver-heart crosstalk, Curr. Opin. Lipidol., 33, 295, 10.1097/MOL.0000000000000845 · DOI
- Pais, 2019, Relationship among fatty liver, specific and multiple-site atherosclerosis, and 10-year framingham score, Hepatol., 69, 1453, 10.1002/hep.30223 · DOI · Paper page
- Pasceri, 2000, Direct proinflammatory effect of C-reactive protein on human endothelial cells, Circulation, 102, 2165, 10.1161/01.cir.102.18.2165 · DOI · Paper page
- Patel, 2019, The interplay between nonalcoholic fatty liver disease and atherosclerotic heart disease, Hepatol., 69, 1372, 10.1002/hep.30410 · DOI · Paper page
- Peng, 2020, Non-alcoholic steatohepatitis: a review of its mechanism, models and medical treatments, Front. Pharmacol., 11, 603926, 10.3389/fphar.2020.603926 · DOI · Paper page
- Peng, 2022, Nonalcoholic fatty liver disease and cardiovascular diseases: a Mendelian randomization study, Metabolism, 133, 155220, 10.1016/j.metabol.2022.155220 · DOI
- Perdomo, 2021, Role of ANGPTL8 in NAFLD improvement after bariatric surgery in experimental and human obesity, Int. J. Mol. Sci., 22, 12945, 10.3390/ijms222312945 · DOI
- Peter, 2018, The hepatokines fetuin-A and fetuin-B are upregulated in the state of hepatic steatosis and may differently impact on glucose homeostasis in humans, Am. J. Physiol. Endocrinol. Metab., 314, E266, 10.1152/ajpendo.00262.2017 · DOI · Paper page
- Petta, 2015, Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease, J. Hepatol., 62, 928, 10.1016/j.jhep.2014.11.030 · DOI · Paper page
- Petta, 2017, Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease, Aliment. Pharmacol. Ther., 45, 510, 10.1111/apt.13889 · DOI · Paper page
- Philips, 2020, Modulating the intestinal microbiota: therapeutic opportunities in liver disease, J. Clin. Transl. Hepatol., 8, 87, 10.14218/JCTH.2019.00035 · DOI
- Pillon, 2013, Cross-talk between skeletal muscle and immune cells: muscle-derived mediators and metabolic implications, Am. J. Physiol. Endocrinol. Metab., 304, E453, 10.1152/ajpendo.00553.2012 · DOI · Paper page
- Plomgaard, 2022, GDF15 is an exercise-induced hepatokine regulated by glucagon and insulin in humans, Front. Endocrinol. (Lausanne), 13, 1037948, 10.3389/fendo.2022.1037948 · DOI
- Pouwels, 2022, Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss, BMC Endocr. Disord., 22, 63, 10.1186/s12902-022-00980-1 · DOI · Paper page
- Purnamasari, 2022, Sarcopenia and chronic complications of type 2 diabetes mellitus, Rev. Diabet. Stud., 18, 157, 10.1900/RDS.2022.18.157 · DOI
- Rafaqat, 2024, Interleukins: pathogenesis in non-alcoholic fatty liver disease, Metabolites, 14, 153, 10.3390/metabo14030153 · DOI
- Raghow, 2013, Betatrophin: a liver-derived hormone for the pancreatic β-cell proliferation, World J. Diabetes., 4, 234, 10.4239/wjd.v4.i6.234 · DOI
- Ratchford, 2014, Carotid artery disease, Vasc. Med., 19, 512, 10.1177/1358863X14557722 · doi:10.1177/1358863x14557722
- Ren, 2023, Relationship between NAFLD and coronary artery disease: a Mendelian randomization study, Hepatol., 77, 230, 10.1002/hep.32534 · DOI
- Ribeiro, 2023, Uremic toxin indoxyl sulfate promotes macrophage-associated low-grade inflammation and epithelial cell senescence, Int. J. Mol. Sci., 24, 8031, 10.3390/ijms24098031 · DOI
- Roman, 2014, Randomized pilot study: effects of an exercise programme and leucine supplementation in patients with cirrhosis, Dig. Dis. Sci., 59, 1966, 10.1007/s10620-014-3086-6 · DOI · Paper page
- Salah, 2021, Relationship of nonalcoholic fatty liver disease and heart failure with preserved ejection fraction, JACC Basic Transl. Sci., 6, 918, 10.1016/j.jacbts.2021.07.010 · DOI
- Santilli, 2014, Clinical definition of sarcopenia, Clin. Cases Min. Bone. Metab., 11, 177
- Schober, 2008, Chemokines in vascular dysfunction and remodeling, Arterioscler. Thromb. Vasc. Biol., 28, 1950, 10.1161/ATVBAHA.107.161224 · DOI · Paper page
- Semmler, 2021, Diet and exercise in NAFLD/NASH: beyond the obvious, Liver. Int., 41, 2249, 10.1111/liv.15024 · DOI · Paper page
- Seo, 2021, Hepatokines as a molecular transducer of exercise, J. Clin. Med., 10, 385, 10.3390/jcm10030385 · DOI
- Sethi, 2021, Metabolic Messengers: tumour necrosis factor, Nat. Metab., 3, 1302, 10.1038/s42255-021-00470-z · DOI · Paper page
- Shimada, 2004, Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism, J. Clin. Invest., 113, 561, 10.1172/JCI19081 · doi:10.1172/jci19081 · Paper page
- Siddiqui, 2015, Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile, Clin. Gastroenterol. Hepatol., 13, 1000, 10.1016/j.cgh.2014.10.008 · DOI · Paper page
- Simons, 2022, Association between de novo lipogenesis susceptibility genes and coronary artery disease, Nutr. Metab. Cardiovasc. Dis., 32, 2883, 10.1016/j.numecd.2022.09.003 · DOI
- Sinha, 2018, Direct effects of thyroid hormones on hepatic lipid metabolism, Nat. Rev. Endocrinol., 14, 259, 10.1038/nrendo.2018.10 · DOI · Paper page
- Solanki, 2023, Emerging role of gut microbiota dysbiosis in neuroinflammation and neurodegeneration, Front. Neurol., 14, 1149618, 10.3389/fneur.2023.1149618 · DOI · Paper page
- Song, 2022, The role of gut-liver Axis in gut microbiome dysbiosis associated NAFLD and NAFLD-HCC, Biomedicines, 10, 524, 10.3390/biomedicines10030524 · DOI
- Stasi, 2022, Obesity-related chronic kidney disease: principal mechanisms and new approaches in nutritional management, Front. Nutr., 9, 925619, 10.3389/fnut.2022.925619 · DOI
- Stefan, 2023, The role of hepatokines in NAFLD, Cell. Metab., 35, 236, 10.1016/j.cmet.2023.01.006 · DOI · Paper page
- Su, 2023, Atherosclerosis: the involvement of immunity, cytokines and cells in pathogenesis, and potential novel therapeutics, Aging. Dis., 14, 1214, 10.14336/AD.2022.1208 · DOI
- Sunaga, 2019, Activation of cardiac AMPK-FGF21 feed-forward loop in acute myocardial infarction: role of adrenergic overdrive and lipolysis byproducts, Sci. Rep., 9, 11841, 10.1038/s41598-019-48356-1 · DOI
- Sveinbjornsson, 2022, Multiomics study of nonalcoholic fatty liver disease, Nat. Genet., 54, 1652, 10.1038/s41588-022-01199-5 · DOI · Paper page
- Tang, 2022, Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: an updated meta-analysis with 135,602 individuals, Clin. Mol. Hepatol., 28, 483, 10.3350/cmh.2021.0406 · DOI
- Taqueti, 2018, Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction, Eur. Heart J., 39, 840, 10.1093/eurheartj/ehx721 · DOI · Paper page
- Targher, 2006, Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease, Diabetes Care, 29, 1325, 10.2337/dc06-0135 · DOI · Paper page
- Targher, 2024, MASLD: a systemic metabolic disorder with cardiovascular and malignant complications, Gut, 73, 691, 10.1136/gutjnl-2023-330595 · DOI · Paper page
- Tilg, 2021, Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity, Nat. Metab., 3, 1596, 10.1038/s42255-021-00501-9 · DOI · Paper page
- Tripathi, 2022, Vitamin B(12) and folate decrease inflammation and fibrosis in NASH by preventing syntaxin 17 homocysteinylation, J. Hepatol., 77, 1246, 10.1016/j.jhep.2022.06.033 · DOI
- Umbro, 2021, Nonalcoholic fatty liver disease and the kidney: a review, Biomedicines, 9, 1370, 10.3390/biomedicines9101370 · DOI
- Valenzuela-Vallejo, 2023, Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: a Multicenter Observational Study, Metabolism, 148, 155694, 10.1016/j.metabol.2023.155694 · DOI
- van der Meer, The ageing male heart: myocardial triglyceride content as independent predictor of diastolic function, Eur. Heart J., 29, 1516, 10.1093/eurheartj/ehn207 · DOI · Paper page
- VanWagner, 2018, New insights into NAFLD and subclinical coronary atherosclerosis, J. Hepatol., 68, 890, 10.1016/j.jhep.2018.01.023 · DOI
- Venkatesh, 2024, Shrinking fat, healing liver: unlocking the metabolic dysfunction associated steatohepatitis puzzle, Hepatobiliary Surg. Nutr., 13, 132, 10.21037/hbsn-23-569 · DOI
- Venniyoor, 2021, The troubling link between non-alcoholic fatty liver disease (NAFLD) and extrahepatic cancers (EHC), Cureus, 13, e17320, 10.7759/cureus.17320 · DOI
- Verma Mkt, 2024, Dietary determinants of metabolic syndrome: focus on the obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), 1, 10.5772/intechopen.114832 · DOI
- Villanova, 2005, Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease, Hepatol., 42, 473, 10.1002/hep.20781 · DOI · Paper page
- Violi, 2023, Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease, Nat. Rev. Cardiol., 20, 24, 10.1038/s41569-022-00737-2 · DOI · Paper page
- Viveiros, 2021, The role of life style modifications in comprehensive non-alcoholic fatty liver disease treatment, Clin. Liver. Dis. Hob., 17, 11, 10.1002/cld.1007 · DOI
- Walker, 2014, Ammonia metabolism and hyperammonemic disorders, Adv. Clin. Chem., 67, 73, 10.1016/bs.acc.2014.09.002 · DOI · Paper page
- Wang, 2024, Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease, Hepatol. Int., 18, 943, 10.1007/s12072-023-10624-8 · DOI
- Wang, 2022, Association of metabolic dysfunction-associated fatty liver disease with kidney disease, Nat. Rev. Nephrol., 18, 259, 10.1038/s41581-021-00519-y · DOI · Paper page
- Wang, 2013, Serum gamma-glutamyltransferase and the risk of heart failure in men and women in Finland, Heart, 99, 163, 10.1136/heartjnl-2012-302972 · DOI · Paper page
- Wannamethee, 2012, Γ-glutamyltransferase, hepatic enzymes, and risk of incident heart failure in older men, Arterioscler. Thromb. Vasc. Biol., 32, 830, 10.1161/ATVBAHA.111.240457 · DOI
- Wegermann, 2023, Serum metabolites are associated with HFpEF in biopsy-proven nonalcoholic fatty liver disease, J. Am. Heart Assoc., 12, e029873, 10.1161/JAHA.123.029873 · DOI
- Wijarnpreecha, 2019, Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA, Eur. J. Gastroenterol. Hepatol., 31, 1121, 10.1097/MEG.0000000000001397 · DOI · Paper page
- Witkowski, 2022, The economic burden of non-alcoholic steatohepatitis: a systematic review, Pharmacoeconomics, 40, 751, 10.1007/s40273-022-01140-y · DOI
- Xiang, 2022, The role of the intestinal microbiota in nonalcoholic steatohepatitis, Front. Endocrinol. (Lausanne), 13, 812610, 10.3389/fendo.2022.812610 · DOI
- Xie, 2023, The associations between modifiable risk factors and nonalcoholic fatty liver disease: a comprehensive Mendelian randomization study, Hepatol., 77, 949, 10.1002/hep.32728 · DOI · Paper page
- Yadav, 2013, Role of leptin and adiponectin in insulin resistance, Clin. Chim. Acta., 417, 80, 10.1016/j.cca.2012.12.007 · DOI · Paper page
- Yan, 2023, Association of fat-to-muscle ratio with non-alcoholic fatty liver disease: a single-centre retrospective study, BMJ Open, 13, e072489, 10.1136/bmjopen-2023-072489 · DOI
- Yang, 2023, Coronary microvascular dysfunction and cardiovascular disease: pathogenesis, associations and treatment strategies, Biomed. Pharmacother., 164, 115011, 10.1016/j.biopha.2023.115011 · DOI
- Yang, 2022, Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction, Front. Cardiovasc. Med., 9, 1120085, 10.3389/fcvm.2022.1120085 · DOI
- Yarasheski, 2002, Serum myostatin-immunoreactive protein is increased in 60-92 year old women and men with muscle wasting, J. Nutr. Health. Aging., 6, 343
- Yoshida, 2020, Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy, Cells, 9, 1970, 10.3390/cells9091970 · DOI · Paper page
- Younossi, Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa, Liver. Int., 44, 1061, 10.1111/liv.15852 · DOI
- Younossi, The changing epidemiology of adult liver transplantation in the United States in 2013-2022: the dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease, Hepatol. Commun., 8, e0352, 10.1097/HC9.0000000000000352 · DOI · Paper page
- Yu, 2022, A pooled analysis of the association between sarcopenia and osteoporosis, Med. Baltim., 101, e31692, 10.1097/MD.0000000000031692 · DOI
- Zaric, 2019, Homocysteine and hyperhomocysteinaemia, Curr. Med. Chem., 26, 2948, 10.2174/0929867325666180313105949 · DOI · Paper page
- Zegeye, 2018, Activation of the JAK/STAT3 and PI3K/AKT pathways are crucial for IL-6 trans-signaling-mediated pro-inflammatory response in human vascular endothelial cells, Cell. Commun. Signal., 16, 55, 10.1186/s12964-018-0268-4 · DOI · Paper page
- Zeng, 2024, Therapeutic management of metabolic dysfunction associated steatotic liver disease, United Eur. Gastroenterol. J., 12, 177, 10.1002/ueg2.12525 · DOI
- Zhang, 2024, Bacteroides and NAFLD: pathophysiology and therapy, Front. Microbiol., 15, 1288856, 10.3389/fmicb.2024.1288856 · DOI
- Zhang, 2019, A review of fibroblast growth factor 21 in diabetic cardiomyopathy, Heart Fail Rev., 24, 1005, 10.1007/s10741-019-09809-x · DOI
- Zhang, 2022, The associations of total testosterone with probable nonalcoholic steatohepatitis and nonalcoholic fatty liver disease fibrotic progression in men with type 2 diabetes: a cross-sectional study, Eur. J. Med. Res., 27, 307, 10.1186/s40001-022-00958-8 · DOI
- Zhang, 2023, PPAR-alpha/gamma agonists, glucagon-like peptide-1 receptor agonists and metformin for non-alcoholic fatty liver disease: a network meta-analysis, J. Int. Med. Res., 51, 3000605231177191, 10.1177/03000605231177191 · DOI
- Zhao, TyG index is positively associated with risk of CHD and coronary atherosclerosis severity among NAFLD patients, Cardiovasc. Diabetol., 21, 123, 10.1186/s12933-022-01548-y · DOI · Paper page
- Zhao, New insights into fibrosis from the ECM degradation perspective: the macrophage-MMP-ECM interaction, Cell Biosci., 12, 117, 10.1186/s13578-022-00856-w · DOI · Paper page
- Zhen, 2023, The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases, Front. Endocrinol. (Lausanne), 14, 1085041, 10.3389/fendo.2023.1085041 · DOI · Paper page
- Zhu, 2023, Two sides of the same coin: non-alcoholic fatty liver disease and atherosclerosis, Vasc. Pharmacol., 154, 107249, 10.1016/j.vph.2023.107249 · DOI
- Zhu, 2021, Efficacy and safety of GLP-1 receptor agonists in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease: a systematic review and meta-analysis, Front. Endocrinol. (Lausanne), 12, 769069, 10.3389/fendo.2021.769069 · DOI
Cited by
MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women
Milani, I., Chinucci, M., Leonetti, F., & Capoccia, D. (2025) · Biomedicines · doi:10.3390/biomedicines13040855 · Cited by 38
“Increased intestinal permeability, or “leaky gut,” leads to the release of microbiota-derived metabolites that are recognized as biomarkers or therapeutic targets for MASLD [211,223].”
InfluentialYashaswini, C. N., Cogliati, B., Qin, T., To, T., Williamson, T., Papp, T. E., Li, K., Rasul, R., Chen, L., Lightstone, A., et al. (2025) · doi:10.1101/2025.02.25.640143 · Cited by 13
The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease
Kotlyarova, A., Iskrina, A., & Kotlyarov, S. (2026) · International journal of molecular sciences · doi:10.3390/ijms27083399 · Cited by 10
Metadata
- Authors
- Sandireddy, R., Sakthivel, S., Gupta, P., Behari, J., Tripathi, M., & Singh, B. K.
- Venue
- Frontiers in Cell and Developmental Biology
- Publisher
- Frontiers Media SA
- Published
- 2024-07-16
- Volume
- 12
- Pages
- 1433857-1433857
- ISSN
- 2296-634X (ISSN-L)
- OpenAlex
- W4400696056
- Cited by
- 211
- References
- 49
- FWCI
- 55.17
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- National Medical Research Council (MOH-OFIRG19may-0002 Duke-NUS-KBrFA/2023/0075)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.